XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK BASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
May 16, 2019
May 15, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock remaining for grants 122,936      
Pricing model used in calculation of grant-date fair value Black-Scholes      
Expected dividend yield 0.00%      
Expected option life 10 years      
Unrecognized compensation expense related to non-vested market-based share awards $ 5,427,714      
Aggregate intrinsic value of options and warrants outstanding and exercisable $ 30,696,511      
Closing stock price of common stock $ 5.23      
Proceeds from Options exercised $ 7,000      
Cashless options exercised 25,000 4,375    
Unamortized value $ 579,822      
Warrant [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Proceed from warrants exercised $ 18,750      
Common Stock [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Options exercised 10,000 30,000    
Minimum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Expected volatility 73.70%      
Risk-free interest rate 3.49%      
Maximum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Expected volatility 76.90%      
Risk-free interest rate 3.94%      
Two Thousands Seven Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Number of common shares available to be purchased through options, issued and outstanding 10,000,000      
Number of shares authorized under plan 2,895,000      
Two Thousands Sixteen Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Number of common shares available to be purchased through options, issued and outstanding 5,712,923      
Number of shares authorized under plan     8,000,000 3,000,000
Common stock remaining for grants 885,314      
Exercisable period 10 years